PADI4 and rheumatoid arthritis: Further studies are needed to analyze the differences between Darrah et al.’s results and our findings, in order to continue to understand the anti-PAD4 response and isotype usage and to further elucidate the utility of anti-PAD4 IgA as a biomarker in RA.